Health
‘This Is a Dangerous Virus’
When bird flu first struck dairy cattle a year ago, it seemed possible that it might affect a few isolated herds and disappear as quickly as it had appeared. Instead, the virus has infected more than 900 herds and dozens of people, killing one, and the outbreak shows no signs of abating.
A pandemic is not inevitable even now, more than a dozen experts said in interviews. But a series of developments over the past few weeks indicates that the possibility is no longer remote.
Toothless guidelines, inadequate testing and long delays in releasing data — echoes of the missteps during the Covid-19 pandemic — have squandered opportunities for containing the outbreak, the experts said.
In one example emblematic of the disarray, a few dairy herds in Idaho that were infected in the spring displayed mild symptoms for a second time in the late fall, The New York Times has learned. In mid-January, the Department of Agriculture said that no new infections in Idaho herds had been identified since October. But state officials publicly discussed milder cases in November.
That a second bout of infections would produce milder symptoms in cattle is unsurprising, experts said, and could be welcome news to farmers. But reinfections suggest that the virus, called H5N1, could circulate on farms indefinitely, creating opportunities for it to evolve into a more dangerous form — a “high-risk” scenario, said Louise Moncla, an evolutionary biologist at the University of Pennsylvania.
“You could easily end up with endemically circulating H5 in dairy herds without symptoms, obscuring rapid or easy detection,” Dr. Moncla said.
It’s impossible to predict whether the virus will evolve the ability to spread among people, let alone when, she and others said. But the worry is that if bird flu finds the right combination of genetic mutations, the outbreak could quickly escalate.
“I’m still not pack-my-bags-and-head-to-the-hills worried, but there’s been more signals over the past four to six weeks that this virus has the capacity” to set off a pandemic, said Richard Webby, an influenza expert at St. Jude Children’s Research Hospital.
Federal officials, too, have subtly altered their tone in discussing the outbreak, now emphasizing how quickly the situation might change.
For the general public, H5N1 is “a low risk, relative to the other risks they face today,” said Dr. Nirav Shah, principal deputy director of the Centers for Disease Control and Prevention. But “100 percent, that could change,” he said. “This is a dangerous virus.”
Health experts emphasize that there are precautions Americans can take: Do not touch sick or dead birds or other animals; get tested if you have flulike symptoms; do not consume raw milk or meat, or feed them to your pets.
If a larger outbreak were to erupt, the federal vaccine stockpile holds a few million doses, although that vaccine might first need updating to match the evolved form of the virus. In either case, officials would have to scramble to produce enough for the population.
The C.D.C. recommends treatment with the antiviral Tamiflu, but studies have shown that the drug does very little to ease illness.
Underlining concerns among many experts is that Robert F. Kennedy Jr., who would lead the federal health department if confirmed, was a vocal critic of Covid vaccines and has said the bird flu vaccines “appear to be dangerous.”
Even if the second Trump administration embraces vaccine development, as the first one did when Covid bore down, it’s unclear how many Americans would roll up their sleeves for the shots. Influenza typically affects children and older adults, and pandemic influenza has sometimes hit young adults the hardest. But the mistrust engendered during Covid-19 may make Americans eschew precautions, at least initially.
An evolving threat
Unlike the coronavirus, which caused havoc with its sudden arrival, influenza viruses typically start off in a specific animal species or in certain geographical regions.
When H5N1 emerged in East Asia nearly three decades ago, it mostly sickened birds. In the years that followed, it infected at least 940 people, nearly all of whom had close, sustained contact with infected birds; roughly half of those people died.
But since January 2022, when the virus was detected in wild aquatic birds in the United States, it has affected more than 136 million commercial, backyard and wild birds, helping to send egg prices soaring. It has also struck dozens of mammalian species, including cats both wild and domesticated, raccoons, bears and sea lions.
For at least a year, H5N1 has been infecting dairy cattle, which were not known to be susceptible to this type of influenza. In some cows, it has had lasting effects, reducing milk production and increasing the odds of spontaneous abortions.
And in 2024, the virus infected 67 Americans, compared with just one in the years before, in 2022. The sources of these infections are not all known; one person may have transmitted the virus to someone in their household.
Many of these developments are classic steps toward a pandemic, said Dr. James Lawler, a director at the University of Nebraska’s Global Center for Health Security. But, he noted, “where those were really supposed to trigger accelerated and amplified actions at the federal, state and local level, we’ve just kind of shrugged when each milestone has passed.”
Infections in dairy herds, which first emerged in Texas, appeared to be declining last summer. But in late August, California announced its first case. The state’s figures soon rose sharply, prompting Gov. Gavin Newsom to declare a public health emergency in December.
“That was sort of a flag to me, like, ‘OK, this hasn’t gone away,’” said Dr. Manisha Juthani, commissioner of the Connecticut Department of Public Health. “Over the last couple of months, it has felt like the tempo has increased,” she said.
Several other recent events have raised the level of alarm among experts. In early December, scientists reported that in a lab setting, a single mutation helped the virus infect human cells more efficiently.
And late last year two people, a 13-year-old Canadian girl and a Louisiana resident older than 65, became seriously ill; previously, most people infected with H5N1 had not experienced severe symptoms. The Louisiana patient, who had health conditions and cared for sick and dying birds, died in early January.
The girl was placed on life support because of organ failure, but eventually recovered. Scientists still do not know how she became infected; her only risk factor was obesity.
Both patients had contracted a new version of the virus that is distinct from the one in dairy cattle and is now widespread in birds. In both individuals, the virus gained mutations during the course of infection that might allow it to better infect people.
“We are clearly now getting novel viruses forming in the wild bird reservoir,” Dr. Moncla said. “It’s become challenging to keep a handle on all of the various threats.”
Some experts see it as particularly worrisome that the virus seems to be in food sources like raw milk and raw pet food. Domesticated cats have died in numerous states, prompting the recall of at least one brand of pet food and new federal guidelines on pet food quality.
“The raw-pet-food thing to me is, I think, quite alarming,” said Dr. Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases.
Pasteurization kills live virus, as does cooking meat at high temperatures. Still, neither procedure is perfect, Dr. Marrazzo noted: “There’s no way that you can police production and sterilization in a way that’s going to make sure 100 percent of the time that food supply is going to be safe.”
A flawed response
In the year since the outbreak began, federal officials have announced other measures to prevent or prepare for a pandemic. But each is deeply flawed, experts said.
The U.S. Department of Agriculture was slow to begin testing H5N1 vaccines for cows, leaving interested companies in limbo. Dr. Marrazzo said that the department had released genetic information from virus samples but had not said where or when they were collected — details that would help scientists track the virus’s evolution.
It is also unclear how many herds are reinfected or have been battling monthslong infections. In Idaho, some herds infected in the spring seemed to recover but showed milder symptoms again in November.
“From the data we have to date, we do not see evidence of new infections or reinfections in previously affected herds, but rather a lack of clearance of the original infection,” a spokesman for the U.S.D.A. said in an emailed response. But outside experts said that the trajectory of symptoms suggested a second round of illness.
The U.S.D.A.’s program to test bulk milk began in December — nearly a year after the outbreak began — and still does not include Idaho. Engaging private companies may help the program move faster.
Ginkgo Bioworks, a company that worked with federal agencies during the Covid pandemic, already assesses roughly half the nation’s commercial milk supply for bacteria, antibiotics and other substances.
Adding H5N1 to the list would be straightforward, so “why wouldn’t we just add assays into this infrastructure that we already have?” said Matt McKnight, a manager at the company’s biosecurity division.
Earlier this month, the Biden administration announced $306 million in new funding, about one-third of it for surveillance, testing and outreach to farmworkers.
But farmworkers in some places like the Texas Panhandle are still unaware of what bird flu is, how it spreads and why it should matter to them, said Bethany Alcauter, director of research and public health programs at the National Center for Farmworker Health.
As a result, she said, many workers still do not use protective gear, including in milk parlors where the virus is thought to spread.
Human testing has been voluntary, and infections have been missed. Few farmworkers have opted to be tested, out of fear of immigration officials or their own employers.
“If you don’t look for it, you won’t find it, right?,” said Dr. Deborah Birx, who served as White House Coronavirus Response Coordinator under President Trump. “This is not about lockdowns or restricting activity. It’s about protecting the individual American by empowering them with the information.”
NEWYou can now listen to Fox News articles!
As GLP-1 weight-loss medications gain traction, the peptide market is experiencing a surge in interest.
A variety of peptides — commonly marketed for weight loss, muscle building, injury recovery and other uses — have emerged as largely unregulated drugs sold through both licensed compounding pharmacies and unverified vendors.
The U.S. Food and Drug Administration is set to evaluate whether to loosen regulations on several peptides during a meeting this summer.
THINKING ABOUT PEPTIDES? DOCTORS REVEAL KEY DOS AND DON’TS AS ‘WILD WEST’ MARKET GROWS
Peptides are short chains of amino acids — the building blocks of proteins — that play key roles in biological functions, according to the National Institutes of Health. Peptide drugs are lab-made versions of natural molecules in the body that are designed to mimic or influence biological signals to treat disease, experts say.
GLP-1s are “incredibly effective at what they do when it comes to changing body composition, benefiting metabolic health, cardiovascular health [and] neurologic health,” the expert said. (iStock)
Though the peptide market has been described as the “Wild West,” demand remains strong, potentially challenging pharmaceutical giants that dominate the GLP-1 market.
Dr. Alex Tatem, an Indiana-based board-certified urologist with expertise in men’s health and peptides, discussed how “life-changing” GLP-1s kicked off the rise of peptides.
“These were all medications that were designed to help people live well and live as healthy as possible.”
“They are incredibly effective at what they do when it comes to changing body composition, benefiting metabolic health, cardiovascular health [and] neurologic health,” he said. “These are truly miracle compounds, and as a result we’ve seen an explosion of interest – not just on the pharmaceutical side or the doctor’s side, but from the general public.”
According to Tatem, the challenge is that nearly all commercial GLP-1 products are administered in a single-dose weekly pen, which works for the “overwhelmingly majority” of patients, but not for everyone.
OZEMPIC ‘MICRODOSING’ IS THE NEW WEIGHT-LOSS TREND: SHOULD YOU TRY IT?
“There are patients I can prescribe tirzepatide to and they can do OK with a once-a-week [dose], but they end up developing nausea with that initial injection – and then by the end of the week, they’re hungry again.”
Because some patients respond better to smaller, more frequent doses — an option not offered by commercial drugs — compounding, or the customization of medications, has grown in popularity, Tatem said.
Several GLP-1 weight loss medications have been approved by the FDA with positive results from consumers. (iStock)
“We’ve had compounding pharmacies that have now developed compounded versions of semaglutide and tirzepatide that allow that sort of dosing flexibility,” he said.
“The reason compounders had to do this was because there was so much demand for GLP-1s that there was actually a national shortage.”
Current legislation allows compounders to step in during widespread national shortages, according to Tatem, prompting the industry to invest millions of dollars into developing and manufacturing these drugs.
PEPTIDES MAY SOON BE EASIER TO GET AMID RFK JR.’S PUSH, BUT EXPERTS WARN OF RISKS
Once commercial pharmaceutical companies could catch back up, compounders continued making these medications in smaller batches for custom doses, allowing for more patient accessibility.
“That creates a huge clash between commercial pharmaceutical companies and compounders, because commercial pharmaceutical companies view that as an infringement of their property,” Tatem noted.
The expert noted a “huge clash” between pharmaceutical companies and compounding pharmacies in peptide production. (iStock)
Tatem raised concerns about the FDA’s regulation of compounding pharmacies, warning that it could limit patients’ access to customized medications.
“That is a real concern for clinicians like me who really care more about patient access, making sure we can get the right medication to the right patients at the right time,” he said.
RFK JR. BACKS EASIER PEPTIDE ACCESS FOR WELLNESS AS DOCTORS RAISE RED FLAGS
Some peptides have been widely administered for more than a decade without major health complications like toxicity or cancer, according to Tatem.
“These are compounds that haven’t gone through the full FDA approval process that you would normally see for a commercial drug, [yet] we didn’t see anything adverse,” he said.
The FDA plans to consider loosening restrictions on several peptides during a summer 2026 meeting. (Issam Ahmed/AFP)
In September 2023, the FDA “quietly” tightened regulation of 19 peptides, making them illegal to manufacture and cutting off patient access.
“They seemed to be working and seemed to be efficacious for patients, and all of a sudden they were banned, which inadvertently ended up contributing to this surge in interest,” Tatem said. “We kind of saw the same thing happen with peptides that we saw with prohibition.”
CLICK HERE FOR MORE HEALTH STORIES
While the rising popularity of GLP-1 drugs has fueled growing public and regulatory interest in peptides, most of the so-called “trendy” peptides still are not available by prescription, according to Tatem.
They may help with injury recovery, skin rejuvenation, sleep improvements and boosting of natural growth hormones, he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“These were all medications that were designed to help people live well and live as healthy as possible,” the doctor told Fox News Digital. “And in reality, that was also their downfall in the American healthcare system, because if you are going to get a drug approved and to market, it has to treat a disease state.”
“These were all medications that were designed to help people live well and live as healthy as possible,” Tatem told Fox News Digital. (iStock)
Tatem confirmed that he’s seen a shift in patients confronting more than just baseline ailments, seeking advice on how to feel their best through new modes like testosterone therapy.
“The desire to function at our highest level is something that we all feel,” he said.
While nothing replaces the fundamentals — getting eight hours of sleep, eating a high-protein diet and maintaining a fitness routine that blends resistance training and cardio — Tatem said individualized treatments such as peptides may help support those healthy habits.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“If you end up pulling a tendon or pulling a hamstring, and you’re just now starting to get some momentum in the gym, that’s really where peptides start to step in,” he added.
Experts advise consumers to avoid gray-market products, to work only with qualified physicians and reputable pharmacies, and to treat peptides as part of a broader health plan — not a shortcut or risk-free supplement.
Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk, is designed to treat type 2 diabetes, but is widely known for its effect on weight loss. Picture date: Wednesday, October 16, 2024. (James Manning/PA Images via Getty Images)
In a statement shared with Fox News Digital, a Novo Nordisk spokesperson said the drugmaker is committed to working with regulators, law enforcement and “other key stakeholders” to ensure “affordable access to safe, effective and FDA-approved GLP-1 obesity medication like Wegovy and to protect patients from unapproved and untested knockoff drugs.”
“The desire to function at our highest level is something that we all feel.”
“Novo Nordisk supports FDA’s recent thorough scientific analysis and conclusion that there is no medical basis or clinical need for the continued mass compounding of unapproved semaglutide and liraglutide drugs,” they went on.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The agency’s decision reaffirms that compounding is meant to be a rare and limited exception to FDA’s gold-standard drug approval framework that ensures that medicines in the U.S. are safe and effective.”
Fox News Digital reached out to the FDA and Eli Lilly for comment.
NEWYou can now listen to Fox News articles!
During a recent episode of her podcast, Gwyneth Paltrow spoke with neuroscientist Dr. Andrew Huberman about retatrutide, a new advancement in GLP-1 (glucagon-like peptide-1) therapies.
In recent years, GLP-1 receptor agonists have become a major focus in discussions around biohacking, longevity and wellness – but they’re not without a multitude of side effects.
Huberman noted that while first-generation weight-loss drugs curbed users’ appetites, they frequently plunged them into massive, rapid caloric deficits.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
Without aggressive resistance training, a high percentage of that lost weight came directly from lean muscle. “People would lose a ton of weight, but they would also lose muscle mass,” Huberman told Paltrow.
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. (iStock)
That is where retatrutide comes in, he said. Unlike older single- or dual-action medications, retatrutide is a triple agonist.
That means it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon – three hormones involved in regulating blood sugar, appetite and metabolism.
WEIGHT-LOSS EXPERTS PREDICT 5 MAJOR TREATMENT CHANGES LIKELY TO EMERGE IN 2026
“Retatrutide is a more mild agonist of GLP-1,” said Huberman. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection.
Without aggressive resistance training, a high percentage of lost weight can come directly from lean muscle mass, said Andrew Huberman. (iStock)
Because of its balanced, multi-receptor approach, Huberman said the drug has a “lower side effect profile” while still allowing people to lose up to a third of their body weight “across a year or so.”
NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS
Most importantly for fitness and longevity advocates, the doctor pointed out that retatrutide seems to have “some muscle sparing effect.”
Because the drug is still moving through official pipelines, a massive gray market of compounding pharmacies and online peptide suppliers has cropped up to meet the growing demand.
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to Lilly’s website, and the company is currently “evaluating its safety and efficacy” in these clinical studies. (iStock)
Huberman issued a strict warning regarding these unregulated online sources, noting that these options “can say 99% purity, but that 1% means there could be some LPS,” referring to lipopolysaccharides, a type of bacterial toxin.
CLICK HERE FOR MORE HEALTH STORIES
“LPS will cause inflammation,” he cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Paltrow echoed the safety concerns, comparing the current “wild-west” peptide craze to the landscape of supplements in the 90s, “where there’s really no third-party testing and it’s kind of word of mouth.”
“Multiple injections over time, I could see where that could become problematic.”
Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to the manufacturer’s website. The company is currently “evaluating its safety and efficacy.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The drug has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial, experts advise.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
-
Arkansas4 minutes agoArkansas officials target repeat fentanyl traffickers as counterfeit pill threat grows
-
Colorado16 minutes agoDenver flights grounded, hundreds delayed as storms hit Colorado’s Eastern Plains
-
Connecticut22 minutes ago3 names added to Connecticut Law Enforcement Memorial in Meriden
-
Delaware28 minutes agoInaugural Delaware Public Health Advocacy Day – 47abc
-
Florida34 minutes agoFlorida officials to pay $485,000 settlement to fired FWC biologist over Charlie Kirk post after his death
-
Georgia40 minutes agoGeorgia town display of military banners raises funds for new veterans memorial
-
Hawaii46 minutes agoHong Kong outrigger canoeists pass Kaiwi Solo test – and aim to tackle it again
-
Idaho52 minutes agoIdaho Rivers United Highlights Year-Round Efforts to Protect the Boise River
